Share
740 Posts.
lightbulb Created with Sketch. 64
clock Created with Sketch. 12/11/18
22:26
Share
Originally posted by antibotter
↑
Below is an announcement regarding AstraZeneca 's first patent application on DEP® Bcl2/xL conjugates. It is the first of several patent applicationsWhy do I bring this up know. So what do I take issue with (a question for the CEO of Starpharma at AGM.......hopefully one of the holders from this forum will ask the question) It is the time line.....starting in October 2017 .....early next year (calendar year 2018) and with no time line in latest October 2018 update Just to reiterate AstraZeneca's first of several patents......several being the operative word Surely based on below information........either trial will start sometime before end of calendar year 2018.......or we need to ask what is the reason for delay......based on Jackie's initial start time of early 2018. Even though AstraZeneca control timing of beginning of trial........it was obvious from first announcment released to ASX more than a year ago.......the CEO was very confident of trial initiation in early half of calendar year 2018 Below is some background on the query in question We can go as far back as the interview conducted by Morgans Finance Limited (Morgans Senior Analyst Scott Power) ......."Under The Microscope with CEO Dr Jackie Fairley 23/10/17 Quotes taken from interview......"That particular product (AZD0046) is going into Phase 1 trials early next year" (calendar year 2018) Repeated later on in interview....."That trial will commence in 2018 first half" (AZD0046) .....obviously referring to calendar year 2018 "AZD0466 is funded by AstraZeneca and clinical trials are expected to commence in 2018" .......Share holder update 19/02/18 "Clinical trials for AZD0466 are expected to commence in 2018" (open to interpretation.......as financial year 2018......one can only speculate within the next 6 weeks.......source half yearly annual report 2018) 26/02/18We can go as far back as the interview conducted by Commsec (Tom Potrowski) Executive Series 14/03/18 "Our AstraZeneca partnership goes from strength to strength and continues to really move along in a very positive manner............ As well as having that lead product (AZD0046) going into the clinic....which we expect that will occur within the next few months" (remember these statements were released in March of 2018). "AstraZeneca recently filed patents which incorporated the dendrimer technology........that patents have a 20 year lifespan" "Dep Irinotecan will go into phase 1 towards the end of the year" (obviously referring to calendar year 2018) AstraZeneca’s DEP Bcl2/xL inhibitors show compelling efficacy and synergy in combination 31/08/1 Starpharma Investor Presentation for Citi Conference 23/10/18 first of several patent applications
Expand
You’re just going over old ground again AB. All keen SPL followers are just as frustrated as yourself about the seeming lack of progress with AZ. At the end of the day though, it is out of JF's control. I am sure AZ are paying for the work in progress but they do not appear to be in a hurry!
(20min delay)
